PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Šenolt, Ladislav
TI  - Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 9--10
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/9.short
4100  - http://mdc.sagepub.com/content/12/9/9.full
AB  - Elevated expression of interleukin-20 (IL-20) and its receptors has been demonstrated in synovium from patients with rheumatoid arthritis (RA) and is thought to be implicated in the pathogenesis of RA. NNC0109-0012 is a novel human monoclonal IgG4 antibody that binds to and neutralizes the activity of IL-20. Results of a Phase 2 study suggest that IL-20 is a potential target for RA therapy.